Inside the New J&J and Consumer Health Company
By

By
J&J plans to separate its pharma and medical devices businesses into one company and its consumer health business into another company. What’s behind the new J&J?

Tracking Expansions in Biomanufacturing
By

By
CDMOs/CMOs are an integral part of bio/pharmaceutical companies’ manufacturing networks. A roundup of biomanufacturing expansion projects.

Podcast 34: Parenteral Drugs: CDMOs/CMOs Expanding
By

By
Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. Key topics: (see Chapter Markers in drop down…

The Latest in the Battle for US Drug-Pricing Reform
By

By
Drug-pricing reform in the US is on the table once again as Congress and the Biden Administration seek to move forward with a new plan. What’s in the plan?

Parenteral Drugs: CDMO/CMOs Expanding
By

By
Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand.

Generics: What is the Next Industry Move?
By

By
Novartis is starting a strategic review of Sandoz, its generics and biosimilars business. Is another wave of industry consolidation in the generics industry on tap?

New Drug Approvals: Blockbuster Potential
By

By
The FDA has approved 42 new molecular entities thus far in 2021. Which products launched or expected to be launched in 2021 have blockbuster potential?
Wave

FDA Issues Draft Guidance on Continuous Manufacturing
By

By
The FDA has issued draft guidance for continuous manufacturing of drug substances and drug products. Industry feedback is due by mid-December. What does the FDA say? 

Manufacturing 4.0: A Look at the Bio/Pharma Industry
By

By
Manufacturing 4.0 is used to denote “smart factories” with increased levels of digitalization and automation. Where does the bio/pharma industry stand?